Novel Molecular Targets in Endometrial Cancer: Mechanisms and Perspectives for Therapy

References

• Liu L, Habeshian TS, Zhang J, et al. Differential trends in rising endometrial cancer incidence by age, race, and ethnicity. JNCI Cancer Spectr. 2023;7(1). doi:10.1093/jncics/pkad001
   Web of Science ®Google Scholar
• Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi:10.3322/caac.21763
   PubMed Web of Science ®Google Scholar
• Tronconi F, Nero C, Giudice E, et al. Advanced and recurrent endometrial cancer: state of the art and future perspectives. Crit Rev Oncol Hematol. 2022;180:103851. doi:10.1016/j.critrevonc.2022.103851
   PubMed Web of Science ®Google Scholar
• Mirza MR, Chase DM, Slomovitz BM, et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N Engl J Med. 2023;388(23):2145–2158. doi:10.1056/NEJMoa2216334
   PubMed Web of Science ®Google Scholar
• Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. N Engl J Med. 2023;388(23):2159–2170. doi:10.1056/NEJMoa2302312
   PubMed Web of Science ®Google Scholar
• O’Malley DM, Bariani GM, Cassier PA, et al. Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: results From the KEYNOTE-158 Study. J Clin Oncol. 2022;40(7):752–761. doi:10.1200/JCO.21.01874
   PubMed Web of Science ®Google Scholar
• Oaknin A, Gilbert L, Tinker AV, et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-A phase I, single-arm study. J Immunother Cancer. 2022;10(1). doi:10.1136/jitc-2021-003777
   PubMed Web of Science ®Google Scholar
• Makker V, Colombo N, Casado Herraez A, et al. Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775. J Clin Oncol. 2023;41(16):2904–2910. doi:10.1200/JCO.22.02152
   PubMed Web of Science ®Google Scholar
• Makker V, Colombo N, Casado Herraez A, et al. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. N Engl J Med. 2022;386(5):437–448. doi:10.1056/NEJMoa2108330
   PubMed Web of Science ®Google Scholar
• Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31(1):12–39. doi:10.1136/ijgc-2020-002230
   PubMed Web of Science ®Google Scholar
• Berek JS, Matias-Guiu X, Creutzberg C, et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet. 2023;162(2):383–394. doi:10.1002/ijgo.14923
   PubMed Web of Science ®Google Scholar
• Morice P, Leary A, Creutzberg C, et al. Endometrial cancer. Lancet. 2016;387(10023):1094–1108. doi:10.1016/S0140-6736(15)00130-0
   PubMed Web of Science ®Google Scholar
• Arciuolo D, Travaglino A, Raffone A, et al. TCGA Molecular Prognostic Groups of Endometrial Carcinoma: current Knowledge and Future Perspectives. Int J Mol Sci. 2022;23(19):19. doi:10.3390/ijms231911684
   Web of Science ®Google Scholar
• Loukovaara M, Pasanen A, Butzow R. Molecular classification of endometrial carcinoma: a clinically oriented review. J Clin Pathol. 2022;75(11):731–738. doi:10.1136/jclinpath-2022-208345
   Web of Science ®Google Scholar
• Walsh CS, Hacker KE, Secord AA, et al. Molecular testing for endometrial cancer: an SGO clinical practice statement. Gynecol Oncol. 2023;168:48–55. doi:10.1016/j.ygyno.2022.10.024
   PubMed Web of Science ®Google Scholar
• Westin SN, Broaddus RR. Personalized therapy in endometrial cancer: challenges and opportunities. Cancer Biol Ther. 2012;13(1):1–13. doi:10.4161/cbt.13.1.18438
   PubMed Web of Science ®Google Scholar
• Corr B, Cosgrove C, Spinosa D, et al. Endometrial cancer: molecular classification and future treatments. BMJ Med. 2022;1(1):e000152. doi:10.1136/bmjmed-2022-000152
   PubMedGoogle Scholar
• McAlpine JN, Chiu DS, Nout RA, et al. Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: an individual patient data meta-analysis. Cancer. 2021;127(14):2409–2422. doi:10.1002/cncr.33516
   PubMed Web of Science ®Google Scholar
• Herrstedt J, Shahin MS, et al. Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. Ann Oncol. 2023;34:S507. doi:10.1016/j.annonc.2023.09.1919
   PubMed Web of Science ®Google Scholar
• Mitamura T, Dong P, Ihira K, et al. Molecular-targeted therapies and precision medicine for endometrial cancer. Jpn J Clin Oncol. 2019;49(2):108–120. doi:10.1093/jjco/hyy159
   PubMed Web of Science ®Google Scholar
• Howitt BE, Shukla SA, Sholl LM, et al. Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. JAMA Oncol. 2015;1(9):1319–1323. doi:10.1001/jamaoncol.2015.2151
   PubMed Web of Science ®Google Scholar
• Mehnert JM, Panda A, Zhong H, et al. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. J Clin Invest. 2016;126(6):2334–2340. doi:10.1172/JCI84940
   PubMed Web of Science ®Google Scholar
• Antill Y, Buchanan DD, Scott CL. Mismatch repair and clinical response to immune checkpoint inhibitors in endometrial cancer. Cancer. 2022;128(6):1157–1161. doi:10.1002/cncr.34024
   PubMed Web of Science ®Google Scholar
• Ruscelli M, Maloberti T, Corradini AG, et al. Prognostic Impact of Pathologic Features in Molecular Subgroups of Endometrial Carcinoma. J Pers Med. 2023;13(5):723. doi:10.3390/jpm13050723
   PubMed Web of Science ®Google Scholar
• Talhouk A, McConechy MK, Leung S, et al. Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017;123(5):802–813. doi:10.1002/cncr.30496
   PubMed Web of Science ®Google Scholar
• Talhouk A, McConechy MK, Leung S, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015;113(2):299–310. doi:10.1038/bjc.2015.190
   PubMed Web of Science ®Google Scholar
• Singh N, Piskorz AM, Bosse T, et al. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies. J Pathol. 2020;250(3):336–345. doi:10.1002/path.5375
   PubMed Web of Science ®Google Scholar
• Jamieson A, Barroilhet L M, McAlpine J N. (2022). Molecular classification in endometrial cancer: Opportunities for precision oncology in a changing landscape. Cancer, 128(15), 2853–2857. 10.1002/cncr.34328
   PubMed Web of Science ®Google Scholar
• Leon-Castillo A, Gilvazquez E, Nout R, et al. Clinicopathological and molecular characterisation of ‘multiple-classifier’ endometrial carcinomas. J Pathol. 2020;250(3):312–322. doi:10.1002/path.5373
   PubMed Web of Science ®Google Scholar
• Ashley CW, Selenica P, Patel J, et al. High-Sensitivity Mutation Analysis of Cell-Free DNA for Disease Monitoring in Endometrial Cancer. Clin Cancer Res. 2023;29(2):410–421. doi:10.1158/1078-0432.CCR-22-1134
   PubMed Web of Science ®Google Scholar
• Grant BM, Pugh TJ, Oza AM. Molecular Monitoring in Endometrial Cancer-Ready for Prime Time? Clin Cancer Res. 2023;29(2):305–308. doi:10.1158/1078-0432.CCR-22-2781
   PubMed Web of Science ®Google Scholar
• Moss EL, Gorsia DN, Collins A, et al. Utility of Circulating Tumor DNA for Detection and Monitoring of Endometrial Cancer Recurrence and Progression. Cancers (Basel). 2020;12(8):2231. doi:10.3390/cancers12082231
   PubMed Web of Science ®Google Scholar
• Lee YJ, Kim SW, et al. 591P Feasibility of longitudinal monitoring of whole blood-based circulating tumour DNA (ctDNA) in patients with endometrial cancer. Ann Oncol. 2022;33:S816–S817. doi:10.1016/j.annonc.2022.07.719
   Web of Science ®Google Scholar
• Sj CK, Chae YK, Sindhu H, et al. Immunotherapy response monitoring using personalized circulating tumor DNA analysis in patients with relapsed gynecologic malignancies. Int j Gynecological Cancer. 2022;32:A410.
   Google Scholar
• Bellone S, McNamara B, Mutlu L, et al. Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers. Int J Mol Sci. 2023;24(10):56.
   Web of Science ®Google Scholar
• Antill Y, Kok PS, Robledo K, et al. Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial. J Immunother Cancer. 2021;9(6):e002255. doi:10.1136/jitc-2020-002255
   PubMed Web of Science ®Google Scholar
• Di Dio C, Bogani G, Di Donato V, et al. The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma. Gynecol Oncol. 2023;169:27–33. doi:10.1016/j.ygyno.2022.11.031
   PubMed Web of Science ®Google Scholar
• Ciciola P, Cascetta P, Bianco C, et al. Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents. J Clin Med. 2020;9(3):675. doi:10.3390/jcm9030675
   PubMed Web of Science ®Google Scholar
• Wu Z, Cui P, Tao H, et al. The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors. Clin Med Insights Oncol. 2021;15:1179554921996288. doi:10.1177/1179554921996288
   Web of Science ®Google Scholar
• Bailly C, Thuru X, Quesnel B. Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times. NAR Cancer. 2020;2(1):zcaa002. doi:10.1093/narcan/zcaa002
   PubMedGoogle Scholar
• Lheureux S, Matei DE, Konstantinopoulos PA, et al. Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer. J Immunother Cancer. 2022;10(3):e004233. doi:10.1136/jitc-2021-004233
   PubMed Web of Science ®Google Scholar
• Rd FK, Arend R, Mccourt C, et al. Atezolizumab and bevacizumab in recurrent endometrial cancer: a phase II multi institutional trial. Int J Gynecol Cancer. 2022;32:A8.
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Gockley AA, Xiong N, et al. Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer. JAMA Oncol. 2022;8(9):1317–1322. doi:10.1001/jamaoncol.2022.2181
   PubMed Web of Science ®Google Scholar
• Post CCB, Westermann AM, Boere IA, et al. Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial). Gynecol Oncol. 2022;165(2):223–229. doi:10.1016/j.ygyno.2022.02.025
   PubMed Web of Science ®Google Scholar
• Madariaga A, Garg S, Tchrakian N, et al. Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma. Nat Commun. 2023;14(1):1452. doi:10.1038/s41467-023-37084-w
   PubMed Web of Science ®Google Scholar
• Bradley HM, Taylor N, Rader JS, et al. An open label, nonrandomized, multisite phase II trial combining bevacizumab, atezolizumab, and rucaparib for the treatment of previously treated recurrent and progressive endometrial cancer. J Clin Oncol. 2022;40(16_suppl):5510. doi:10.1200/JCO.2022.40.16_suppl.5510
   Web of Science ®Google Scholar
• Westin SN, Moore K, Chon HS, et al. Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: the Phase III DUO-E Trial. J Clin Oncol. 2023;101200JCO2302132.
   Google Scholar
• Hk CN, Hudson E, Galli F, et al. LBA49-Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial cancer. Ann Oncol. 2023;34:S1254–S1335.
   Web of Science ®Google Scholar
• MacKay HJ, Freixinos VR, Fleming GF. Therapeutic Targets and Opportunities in Endometrial Cancer: update on Endocrine Therapy and Nonimmunotherapy Targeted Options. Am Soc Clin Oncol Educ Book. 2020;40:1–11. doi:10.1200/EDBK_280495
   PubMedGoogle Scholar
• Aghajanian C, Sill MW, Darcy KM, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2011;29(16):2259–2265. doi:10.1200/JCO.2010.32.6397
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Filiaci V, Dizon DS, et al. A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol. 2018;150(2):274–281. doi:10.1016/j.ygyno.2018.05.018
   PubMed Web of Science ®Google Scholar
• Thiel KW, Devor EJ, Filiaci VL, et al. TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: an NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2022;40(28):3289–3300. doi:10.1200/JCO.21.02506
   PubMed Web of Science ®Google Scholar
• Lorusso D, Ferrandina G, Colombo N, et al. Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial. Gynecol Oncol. 2019;155(3):406–412. doi:10.1016/j.ygyno.2019.10.013
   PubMed Web of Science ®Google Scholar
• Castonguay V, Lheureux S, Welch S, et al. A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia. Gynecol Oncol. 2014;134(2):274–280. doi:10.1016/j.ygyno.2014.05.016
   PubMed Web of Science ®Google Scholar
• Dhani NC, Hirte HW, Wang L, et al. Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: a Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86). Clin Cancer Res. 2020;26(11):2477–2486. doi:10.1158/1078-0432.CCR-19-2576
   PubMed Web of Science ®Google Scholar
• Wagner VM, Backes FJ. Do Not Forget about Hormonal Therapy for Recurrent Endometrial Cancer: a Review of Options, Updates, and New Combinations. Cancers (Basel). 2023;15(6):1799. doi:10.3390/cancers15061799
   PubMed Web of Science ®Google Scholar
• Ethier JL, Desautels DN, Amir E, et al. Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis. Gynecol Oncol. 2017;147(1):158–166. doi:10.1016/j.ygyno.2017.07.002
   PubMed Web of Science ®Google Scholar
• Fiorica JV, Brunetto VL, Hanjani P, et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92(1):10–14. doi:10.1016/j.ygyno.2003.11.008
   PubMed Web of Science ®Google Scholar
• Heudel P, Frenel JS, Dalban C, et al. Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: the Victoria Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial. JAMA Oncol. 2022;8(7):1001–1009. doi:10.1001/jamaoncol.2022.1047
   PubMed Web of Science ®Google Scholar
• Avila M, Grinsfelder MO, Pham M, et al. Targeting the PI3K Pathway in Gynecologic Malignancies. Curr Oncol Rep. 2022;24(12):1669–1676. doi:10.1007/s11912-022-01326-9
   PubMed Web of Science ®Google Scholar
• Westin SN, Sill MW, Coleman RL, et al. Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: an NRG Oncology/GOG study. Gynecol Oncol. 2019;155(3):420–428. doi:10.1016/j.ygyno.2019.09.024
   PubMed Web of Science ®Google Scholar
• Zw KK, McCourt C, Mitchell EP, et al. Ipatasertib in Patients with Tumors with AKT Mutations: results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1K. Eur J Cancer. 2022;174:S8–9. doi:10.1016/S0959-8049(22)00824-3
   Web of Science ®Google Scholar
• Fader AN, Roque DM, Siegel E, et al. Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): updated Overall Survival Analysis. Clin Cancer Res. 2020;26(15):3928–3935. doi:10.1158/1078-0432.CCR-20-0953
   PubMed Web of Science ®Google Scholar
• Rm AE, Mangat PP, Garrett-Mayer E, et al. Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: results From the TAPUR Study. J Clin Oncol Precision Oncol. 2023;7:e2200609.
   PubMed Web of Science ®Google Scholar
• Jhaveri KL, Wang MV, et al. Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Ann Oncol. 2019;30(11):1821–1830. doi:10.1093/annonc/mdz291
   PubMed Web of Science ®Google Scholar
• Nishikawa T, Hasegawa K, Matsumoto K, et al. Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): the STATICE Trial. J Clin Oncol. 2023;41(15):2789–2799. doi:10.1200/JCO.22.02558
   PubMed Web of Science ®Google Scholar
• Oaknin A, Oh D, et al. LBA34-Trastuzumab deruxtecan (T-Dxd) for pretreated patients (pts) with HER2-expressing solid tumors: primary analysis from the DESTINY-PanTumor02 (DP-02) study. Ann Oncol. 2023;34:S1254–S1335.
   Google Scholar
• Sd MKN, Du Y, Li X, et al. Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: a multicenter, open-label, first-in-human, phase 1/2a study. J Clin Oncol. 2023;41:abst 3023.
   Google Scholar
• La LFJ, Ray-Coquard IL, Asselain B, et al. LBA42-Olaparib vs placebo as maintenance therapy after platinum-based chemotherapy in advanced/metastatic endometrial cancer patients: the GINECO randomized phase IIb UTOLA trial. Ann Oncol. 2023;34:S1254–S1335.
   Web of Science ®Google Scholar
• Liu JF, Xiong N, Campos SM, et al. Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma. J Clin Oncol. 2021;39(14):1531–1539. doi:10.1200/JCO.20.03167
   PubMed Web of Science ®Google Scholar
• Oza A. ADAGIO: a phase IIb, open-label, single-arm, multicenter study, assessing the efficacy and safety of adavoosertib (AZD1775) as treatment for recurrent or persistent uterine serous carcinoma. Gynecol Oncol. 2023;176:S33. doi:10.1016/j.ygyno.2023.06.512
   Web of Science ®Google Scholar
• Kn PS M, Flachook GS, Fontana E, et al. 680P-First results from the phase I trial of the ATR inhibitor, ART0380, in advanced solid tumors. Ann Oncol. 2023;34:S458–S497.
   Google Scholar
• Italiano A, Infante JR, Shapiro GI, et al. Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors. Ann Oncol. 2018;29(5):1304–1311. doi:10.1093/annonc/mdy076
   PubMed Web of Science ®Google Scholar
• Lee EK, Simpkins F, et al. MYTHIC: first-in-human biomarker-driven phase I trial of first-in-class PKMYT1 lunresertib alone and with ATR inhibitor camonsertib in solid tumors with CCNE1 amplification or deleterious alterations in FBXW7 or PPP2R1A. Presented at the 2023 AACR-NCI-EORTC Conference, October 11-15 2023, Boston MA. 2023.
   Google Scholar
• Huang P, Fan X, Yu H, et al. Glucose metabolic reprogramming and its therapeutic potential in obesity-associated endometrial cancer. J Transl Med. 2023;21(1):94. doi:10.1186/s12967-022-03851-4
   PubMed Web of Science ®Google Scholar
• Madariaga A, Goodwin PJ, Oza AM. Metformin in Gynecologic Cancers: opening a New Window for Prevention and Treatment? Clin Cancer Res. 2020;26(3):523–525. doi:10.1158/1078-0432.CCR-19-3645
   PubMed Web of Science ®Google Scholar
• Soliman PT, Westin SN, Iglesias DA, et al. Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: a Multi-Center, Single Arm, Phase II Study. Clin Cancer Res. 2020;26(3):581–587. doi:10.1158/1078-0432.CCR-19-0471
   PubMed Web of Science ®Google Scholar
• Rodrigues M, Follana P, et al. Safety and efficacy of olaparib combined to metronomic cyclophosphamide and metformin in recurrent advanced/metastatic endometrial cancer patients: ENDOLA trial. Cancer Res. 2022;82:CT005. doi:10.1158/1538-7445.AM2022-CT005
   Web of Science ®Google Scholar
• Kanda R, Hiraike H, Wada-Hiraike O, et al. Expression of the glucagon-like peptide-1 receptor and its role in regulating autophagy in endometrial cancer. BMC Cancer. 2018;18(1):657. doi:10.1186/s12885-018-4570-8
   PubMed Web of Science ®Google Scholar
• Wr ZH, Wang L, Tian Q, et al. Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner. J Physiol Endocrinol Metab. 2014;306:E1431–E1441. doi:10.1152/ajpendo.00017.2014
   PubMed Web of Science ®Google Scholar
• Zhao WZ, Zhou X, Sun Z. Liraglutide inhibits the proliferation and promotes the apoptosis of MCF-7 human breast cancer cells through downregulation of microRNA-27a expression. Mol Med Rep. 2018;17(4):5202–5212. doi:10.3892/mmr.2018.8475
   PubMed Web of Science ®Google Scholar
• Scafoglio C, Hirayama BA, Kepe V, et al. Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci U S A. 2015;112(30):E4111–4119. doi:10.1073/pnas.1511698112
   PubMed Web of Science ®Google Scholar
• Reyes HD, Thiel KW, Carlson MJ, et al. Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers. Mol Diagn Ther. 2014;18(2):137–151. doi:10.1007/s40291-013-0070-3
   PubMed Web of Science ®Google Scholar
• Vergote I, Perez-Fidalgo JA, Hamilton EP, et al. Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer. J Clin Oncol. 2023;JCO2202906.
   Google Scholar
• de Bono JS, Concin N, Hong DS, et al. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20(3):383–393. doi:10.1016/S1470-2045(18)30859-3
   PubMed Web of Science ®Google Scholar
• Karpel HC, Powell SS, Pothuri B. Antibody-Drug Conjugates in Gynecologic Cancer. Am Soc Clin Oncol Educ Book. 2023;43(43):e390772. doi:10.1200/EDBK_390772
   PubMedGoogle Scholar
• Moore KN, Borghaei H, Dm O, et al. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in patients with solid tumors. Cancer. 2017;123(16):3080–3087. doi:10.1002/cncr.30736
   PubMed Web of Science ®Google Scholar
• Oaknin B, Martin LP, O’Malley D, et al. 741M0-Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FOLRa) antibody drug conjugate (ADC), demonstrate clinical activity in recurrent/progressive epithelial endometrial cancer (EEC): STRO-002-GM1 phase I dose expansion. Ann Oncol. 2023;34:S507–S542.
   PubMed Web of Science ®Google Scholar
• Santin A, Siegel SR, Harold J, et al. Preliminary results of a phase III triaal with sacituzumab govitecan-hziy in patients with recurrent endometrial carcinoma overexpressing Trop-2. J Clin Oncol. 2023;41:5599. doi:10.1200/JCO.2023.41.16_suppl.5599
   Web of Science ®Google Scholar
• Zong L, Yu S, Mo S, et al. B7-H4 Further Stratifies Patients With Endometrial Cancer Exhibiting a Nonspecific Molecular Profile. Arch Pathol Lab Med. 2023;147(11):1288–1297. doi:10.5858/arpa.2022-0182-OA
   PubMed Web of Science ®Google Scholar
• Lakhani N, Call JA, et al. 660M0-First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: preliminary results of a phase I study (SGNBH4V-001). Ann Oncol. 2023;34:S458–497.
   Google Scholar
• Tarantino P, Carmagnani Pestana R, Corti C, et al. Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 2022;72(2):165–182. doi:10.3322/caac.21705
   PubMed Web of Science ®Google Scholar
• Makker V, MacKay H, Ray-Coquard I, et al. Endometrial cancer. Nat Rev Dis Primers. 2021;7(1):88. doi:10.1038/s41572-021-00324-8
   PubMed Web of Science ®Google Scholar
• Dubil EA, Tian C, Wang G, et al. Racial disparities in molecular subtypes of endometrial cancer. Gynecol Oncol. 2018;149(1):106–116. doi:10.1016/j.ygyno.2017.12.009
   PubMed Web of Science ®Google Scholar
• Whelan K, Dillon M, Strickland KC, et al. TP53 mutation and abnormal p53 expression in endometrial cancer: associations with race and outcomes. Gynecol Oncol. 2023;178:44–53. doi:10.1016/j.ygyno.2023.09.009
   PubMed Web of Science ®Google Scholar
• Weigelt B, Marra A, Selenica P, et al. Molecular Characterization of Endometrial Carcinomas in Black and White Patients Reveals Disparate Drivers with Therapeutic Implications. Cancer Discov. 2023;13(11):2356–2369. doi:10.1158/2159-8290.CD-23-0546
   PubMedGoogle Scholar
• Pb SAA, Backes F, Thaker P, et al. Genomic alterations, molecularly targeted therapy and race: real world data from the Endometrial Cancer Molecularly Targeted Therapy Consortium (LBA 8). Gynecol Oncol. 2022;166:S52–S53. doi:10.1016/S0090-8258(22)01301-4
   Web of Science ®Google Scholar
• Urick ME, Bell DW. Clinical actionability of molecular targets in endometrial cancer. Nat Rev Cancer. 2019;19(9):510–521. doi:10.1038/s41568-019-0177-x
   PubMed Web of Science ®Google Scholar
• Chen W, Sun Z, Lu L. Targeted Engineering of Medicinal Chemistry for Cancer Therapy: recent Advances and Perspectives. Angew Chem Int Ed Engl. 2021;60(11):5626–5643. doi:10.1002/anie.201914511
   PubMed Web of Science ®Google Scholar